Hubert Serve

Carboplatin/etoposide induces remission of metastasised malignant peripheral nerve tumours (malignant schwannoma) refractory to first-line therapy.

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain.

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

Quantification of cyclin A1 and glyceraldehyde-3-phosphate dehydrogenase expression in testicular biopsies of infertile patients by fluorescence real-time RT-PCR.

Cyclin A1 and gametogenesis in fertile and infertile patients: a potential new molecular diagnostic marker.

A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571.

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.

Cyclin A1 is highly expressed in aggressive testicular germ cell tumors.

Successive increases in human cyclin A1 promoter activity during spermatogenesis in transgenic mice.

Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.

Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells.

Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.

Re: Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development.

MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.

Redirection of oncoproteins to kill cancer cells.

E- and A-type cyclins as markers for cancer diagnosis and prognosis.

Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia.

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.

Multicolor karyotyping in acute myeloid leukemia.

High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets.

Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.

Epigenetic regulation of tumor suppressors in t(8:21)-containing AML.

Identification of interaction partners and substrates of the cyclin A1-CDK2 complex.

Flt3 receptor tyrosine kinase as a drug target in leukemia.

Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.

S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer.

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma.

Influence of keratinocyte growth factor on clonal growth of epithelial tumor cells, lymphoma and leukemia cells and on sensitivity of tumor cells towards 5-fluorouracil in vitro.

The cyclin A1-CDK2 complex regulates DNA double-strand break repair.

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RARalpha and regulates differentiation of hematopoietic cells.

RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.

Genome-wide screening for prognosis-predicting genes in early-stage non-small-cell lung cancer.

In vivo analyses of UV-irradiation-induced p53 promoter binding using a novel quantitative real-time PCR assay.

Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer.

Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias.

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

Expression patterns of mitotic and meiotic cell cycle regulators in testicular cancer and development.

Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells.

Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases.

Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant.

Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells.

Signal transduction of oncogenic Flt3.

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

The molecular pathogenesis of acute myeloid leukemia.

Acute myeloid leukemia presenting with a uterus tumor.

Treatment of older patients with AML.

Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.

First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.

Treatment of AML in biological subgroups.

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.

Emerging Flt3 kinase inhibitors in the treatment of leukaemia.

Wnt signaling regulates transendothelial migration of monocytes.

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors.

Decitabine and vitamin D3 differentially affect hematopoietic transcription factors to induce monocytic differentiation.

The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia.

DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.

Oncogenic signaling in acute myeloid leukemia.

Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

Flt3-dependent transformation by inactivating c-Cbl mutations in AML.

DNA damage response involves modulation of Ku70 and Rb functions by cyclin A1 in leukemia cells.

New molecular therapy targets in acute myeloid leukemia.

CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha.

Analysis of the genetic interactions between Cyclin A1, Atm and p53 during spermatogenesis.

Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip.

Identification of acute myeloid leukaemia associated microRNA expression patterns.

Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice.

Adaptor protein Lnk associates with Tyr(568) in c-Kit.

Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia.

Activation of Wnt signalling in acute myeloid leukemia by induction of Frizzled-4.

S100A2 induces metastasis in non-small cell lung cancer.

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.

Construction and application of an inducible system for homogenous expression levels in bulk cell lines.

An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.

E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.

Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.

Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model.

The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer.

Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia.

Low SMC1A protein expression predicts poor survival in acute myeloid leukemia.

Adaptor protein Lnk inhibits c-Fms-mediated macrophage function.

Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations.

The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells.

Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.

The European LeukemiaNet: achievements and perspectives.

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival.

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.

AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein.

Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling.

Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation.

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.

Inhibitor of cyclin-dependent kinase (CDK) interacting with cyclin A1 (INCA1) regulates proliferation and is repressed by oncogenic signaling.

High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.

Antifungal management and resource use in patients with acute myeloid leukaemia after chemotherapy--retrospective analysis of changes over 3 yr in a German hospital.

Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy.

Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.

Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia.

Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene.

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.

SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control.

IT behind a platform for Translational Cancer Research - concept and objectives.

A special query tool in the hospital information system to recognize patients and to increase patient numbers for clinical trials.

Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells.

A novel hierarchical prognostic model of AML solely based on molecular mutations.

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.

Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia.

Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.

β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis.

High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

Cutting edge: feed-forward activation of phospholipase Cγ2 via C2 domain-mediated binding to SLP65.

Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.

[Patient blood management--How does it work in practice?--the interdisciplinary cooperation].

A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.

PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation.

CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells.

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.

Allogeneic Stem-Cell Transplantation in Patients With NPM1-Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial.

FLT3-ITD and TLR9 employ Bruton's tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation.